Bodd builds a proprietary 3D body-scanning device that captures precise human measurements in seconds, enabling more accurate uniform fittings and health-related body composition assessments. Initially launched as a custom apparel company, the founders—Rob Fisher and David McLaughlin—pivoted in 2019 to focus exclusively on the scanning technology and fully exited the clothing business in 2023. The scanners are marketed to industries such as defense, emergency services, healthcare and wellness, where exact sizing or biometric data is critical. Demand has been buoyed by trends like rapid weight-loss treatments (e.g., Ozempic) that create frequent size changes and drive the need for updated measurements. The company monetises through hardware sales and recurring software licences, though specific revenue figures were not disclosed. Following its latest raise, Bodd’s post-money valuation stands at approximately $110 million. Capital from the new round will be used to expand sales and scale manufacturing.

Total raised

$15M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2025